Oncotarget

Research Papers:

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer

Wei Zhang _ and Zhifen Zhang

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:86621-86629. https://doi.org/10.18632/oncotarget.13361

Metrics: PDF 1378 views  |   HTML 1588 views  |   ?  


Abstract

Wei Zhang1, Zhifen Zhang1

1Department of Gynecology, Nanjing Medical University, Affiliated Hangzhou Hospital, Hangzhou First People’s Hospital, 310006, Hangzhou, China

Correspondence to:

Zhifen Zhang, email: [email protected]

Keywords: ERCC2, XRCC2, ovarian cancer, meta-analysis, single nucleotide polymorphism

Received: October 07, 2016    Accepted: October 29, 2016    Published: November 15, 2016

ABSTRACT

Recent studies explored XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer (OC) risk. However, the association between these two single nucleotide polymorphisms and OC risk remains conflicting. Thus, we conducted a comprehensive systematic review and meta-analysis to investigate the association. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. 15 case-control studies published in 11 papers including 4,757 cases and 8,431 controls were included in this meta-analysis. No associations were obtained between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analyses of Hardy–Weinberg equilibrium status indicated that rs3218536 polymorphism was associated with the decreased risk of OC when in analysis of combined HWE positive studies. In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13361